$5.58 1.5%
ARDX Stock Price vs. AI Score
Data gathered: December 4

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Ardelyx (ARDX)

Analysis generated November 19, 2024. Powered by Chat GPT.

Ardelyx is a biopharmaceutical company that focuses on the development and commercialization of small molecule medicines to treat cardiorenal and gastrointestinal diseases. As a specialty pharmaceutical player, Ardelyx’s lead programs and developmental focuses place it in promising yet competitive market segments. The company's current flagship product continues to attract investor interest and market speculation.

Read full AI stock Analysis

Stock Alerts - Ardelyx (ARDX)

company logo Ardelyx | December 4
Price is up by 5.1% in the last 24h.
company logo Ardelyx | November 28
Insider Alert: RAAB MICHAEL is selling shares
company logo Ardelyx | November 27
Price is up by 5.4% in the last 24h.
company logo Ardelyx | November 23
Insider Alert: Williams Laura A is selling shares

About Ardelyx

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.


Ardelyx
Price $5.58
Target Price Sign up
Volume 4,390,000
Market Cap $1.31B
Year Range $4.5 - $9.31
Dividend Yield 0%
Analyst Rating 75% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2498M81M18M-810,0002.2M-0.003
Q2 '2473M74M-870,000-16M-13M-0.070
Q1 '2444M60M-16M-27M-24M-0.110
Q4 '2333M54M-20M-29M-26M-0.120
Q3 '2355M41M14M6.6M8.9M0.030

Insider Transactions View All

RAAB MICHAEL filed to sell 1,150,385 shares at $5.4.
November 27 '24
Blanks Robert filed to sell 314,421 shares at $4.8.
November 22 '24
GRAMMER ELIZABETH A filed to sell 185,334 shares at $4.8.
November 22 '24
Renz Justin A filed to sell 291,139 shares at $4.8.
November 22 '24
Rosenbaum David P. filed to sell 151,373 shares at $4.8.
November 22 '24

What is the Market Cap of Ardelyx?

The Market Cap of Ardelyx is $1.31B.

What is the current stock price of Ardelyx?

Currently, the price of one share of Ardelyx stock is $5.58.

How can I analyze the ARDX stock price chart for investment decisions?

The ARDX stock price chart above provides a comprehensive visual representation of Ardelyx's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ardelyx shares. Our platform offers an up-to-date ARDX stock price chart, along with technical data analysis and alternative data insights.

Does ARDX offer dividends to its shareholders?

As of our latest update, Ardelyx (ARDX) does not offer dividends to its shareholders. Investors interested in Ardelyx should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Ardelyx?

Some of the similar stocks of Ardelyx are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.